DNA Script Signs Innovation Development Contract With French Defence Innovation Agency to Enable On-Demand Diagnostics Against Emerging Biothreats
28.1.2021 09:00:00 EET | Business Wire | Press release
DNA Script, a leading pioneer in enabling DNA synthesis on demand, today announced a partnership with the French Defence Innovation Agency, in liaison with the French Armament General Directorate (DGA), to develop a prototype for rapid mobile manufacturing of DNA primers and probes, key components of detection and diagnostic tests for pathogens. The joint project will employ DNA Script’s novel enzymatic synthesis platform to quickly generate high-fidelity nucleic acids. The prototypes to be developed by DNA Script will be evaluated by the DGA. As part of the agreement, DNA Script will receive $1.6 million in funding.
In an emerging biothreat, like the ongoing COVID-19 pandemic, conventional sources of supply for key reagents (qPCR primers and probes in particular) become a limiting factor. Therefore, it is essential to enable an on-demand, agile source for custom reagent manufacturing. The DGA identified DNA Script’s SYNTAX™ platform, a benchtop instrument that synthesizes high-quality, custom nucleic acids in hours, a key capability that enables scientists to iterate faster in response to emerging biothreats, as a potential solution. The underlying core technology, enzymatic DNA synthesis, mimics the enzymatic process used by nature, thus avoiding the use of harsh organic solvents or the need to avoid the presence of air or water as required by conventional chemical approaches commercially available today.
DNA Script will adapt its SYNTAX™ platform to enable the synthesis of the DNA reagents such as Taqman probes, required in PCR-based molecular biology diagnostics. SYNTAX™ is the world’s first instrument to use an enzymatic process for nucleic acid synthesis.
“We are thrilled to collaborate with the French Ministry for Armed Forces on this important initiative to rapidly detect, characterize and mitigate threats from newly emerging or engineered pathogens,” said Thomas Ybert, Chief Executive Officer of DNA Script. “We believe that the speed, efficiency and ease of use of our SYNTAX™ nucleic acid printer and underlying enzymatic synthesis technology will be critical in addressing future pandemics.”
About DNA Script
Founded in 2014 in Paris, DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science. The company is pioneering an alternative to traditional DNA synthesis called enzymatic DNA synthesis, or EDS, making this technology accessible to labs with the world’s first benchtop enzymatic synthesis instrument, SYNTAX™. By putting DNA synthesis back in the lab, DNA Script is transforming life science research through innovative technology that gives researchers unprecedented autonomy. www.dnascript.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210127005926/en/
Contact information
Press in the US
Seismic
Eric Schubert
415-939-4366
eric@teamseismic.com
Press in Europe
ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59
caroline@alizerp.com
DNA Script
publicrelations@dnascript.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 202622.4.2026 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): Q1 2026 Key figures1 › Revenue of EUR 1,547.0 million, up 4.5% organically, and down 0.8% year-on-year › Strong organic growth from Marine & Offshore at +11.2% and Buildings & Infrastructure at +7.3% with moderate growth for Consumer Products Services at +4.3%, Certification at +2.3%, Agri-Food & Commodities at +2.1%, and Industry at +0.7%, › Stable scope effect of (0.1)%, from bolt-on acquisitions (+1.8% contribution), net of disposals (-1.9%), › Negative currency impact of 5.2%, resulting from the euro’s appreciation against most currencies. Q1 2026 Highlights › Maintained steady performance across most regions, in an environment marked by disruptions related to the conflict in the Middle East; growth in the Industry business impacted by the delays of Opex-related services mainly in the Middle East, › Continued progress in execution of the Group’s LEAP | 28 strategy, pivoting its portfolio towards higher‑growth and higher‑margin activities. Four acquisiti
Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 202622.4.2026 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): Q1 2026 Key figures1 › Revenue of EUR 1,547.0 million, up 4.5% organically, and down 0.8% year-on-year › Strong organic growth from Marine & Offshore at +11.2% and Buildings & Infrastructure at +7.3% with moderate growth for Consumer Products Services at +4.3%, Certification at +2.3%, Agri-Food & Commodities at +2.1%, and Industry at +0.7%, › Stable scope effect of (0.1)%, from bolt-on acquisitions (+1.8% contribution), net of disposals (-1.9%), › Negative currency impact of 5.2%, resulting from the euro’s appreciation against most currencies. Q1 2026 Highlights › Maintained steady performance across most regions, in an environment marked by disruptions related to the conflict in the Middle East; growth in the Industry business impacted by the delays of Opex-related services mainly in the Middle East, › Continued progress in execution of the Group’s LEAP | 28 strategy, pivoting its portfolio towards higher‑growth and higher‑margin activities. Four acquisiti
4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis22.4.2026 08:00:00 EEST | Press release
4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to 4P004 for the treatment of knee osteoarthritis in patients with synovitis who have not benefited from at least two prior pharmacological therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421591087/en/ 4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis This designation highlights both the serious burden of knee osteoarthritis and the persistent lack of disease-modifying treatment options. It also reflects the strong scientific rationale supporting the 4P004 development program, including its targeted intra-articular approach and the role of synovitis as a key marker of disease progression. 4P004 is a
4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis22.4.2026 08:00:00 EEST | Press release
4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to 4P004 for the treatment of knee osteoarthritis in patients with synovitis who have not benefited from at least two prior pharmacological therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421591087/en/ 4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis This designation highlights both the serious burden of knee osteoarthritis and the persistent lack of disease-modifying treatment options. It also reflects the strong scientific rationale supporting the 4P004 development program, including its targeted intra-articular approach and the role of synovitis as a key marker of disease progression. 4P004 is a
LTM Wins Two Google Cloud Partner of the Year Awards for 202622.4.2026 05:30:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, announced today that it has received two Google Cloud Partner of the Year 2026 Awards. LTM is being recognized for its achievements in the Google Cloud ecosystem, helping joint customers to drive high-impact, scalable cloud transformations. LTM won the Google Cloud Partner of the Year Award in the Media & Entertainment category by modernizing a global media company's complex data estate with BigQuery. The transformation improved speed, lowered costs, and provided a scalable foundation, enabling real-time analytics and AI-ready pipelines. This approach offers a repeatable model for data modernization in Media and Entertainment industry. Additionally, LTM was honoured with another Google Cloud Partner of the Year Award for Infrastructure Modernization in North America and the transformation of the ERP landscape for a global leader in healthcare services. This resulted in faster time to market, modern scalable ecosys
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom